Reuters logo
BRIEF-Enanta says CHMP gives positive opinion for AbbVie's hep C treatment for patients with genotype 1B
February 27, 2017 / 11:51 AM / 7 months ago

BRIEF-Enanta says CHMP gives positive opinion for AbbVie's hep C treatment for patients with genotype 1B

Feb 27 (Reuters) - Enanta Pharmaceuticals Inc

* Enanta announces CHMP grants positive opinion for an eight-week treatment option with Abbvie’s Viekirax® (ombitasvir/paritaprevir/ritonavir tablets) + exviera® (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

* Says Abbvie’s EMA label expansion is supported by 98 percent svr 12 rate in patients in dedicated phase 3b garnet study

* Says chmp positive opinion is supported by data from dedicated phase 3b garnet study Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below